about
sameAs
Translating biotechnology to knowledge-based innovation, peace, and development? Deploy a Science Peace Corps--an open letter to world leadersProgress in pharmacogenetics: consortiums and new strategiesReady to put metadata on the post-2015 development agenda? Linking data publications to responsible innovation and science diplomacy.Oxidative polymorphism of debrisoquine in Parkinson's diseaseATA homozigosity in the IL-10 gene promoter is a risk factor for schizophrenia in Spanish females: a case control study.Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms.Fixed combinations of neuroleptics with antidepressants: potential risks and estimation of use.Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden.Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.Success stories in genomic medicine from resource-limited countries.Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake InhibitorsClinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs.Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism.Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population.A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project.CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trialsA tribute to josé maría ("chema") cantú.Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine.Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study.Pharmacogenetics of clinical response to risperidone.Present status and perspective of pharmacogenetics in Mexico.Cytochrome P450 genetic polymorphisms of Mexican indigenous populations.Pharmacogenetic potential biomarkers for carbamazepine adverse drug reactions and clinical response.Venlafaxine pharmacokinetics focused on drug metabolism and potential biomarkers.Clinical drug-drug interactions: focus on venlafaxine.Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations.Pharmacogenetics in Central American healthy volunteers: interethnic variability.Pharmacogenomic information in drug labels: European Medicines Agency perspective.Pharmacogenetics of adverse reactions to antiepileptic drugs.Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes.Predictive biomarkers candidates for patients with metastatic colorectal cancer treated with bevacizumab-containing regimen.What is the future of pharmacogenomics in pain management?Pharmacogenetics and ethnicity: relevance for clinical implementation, clinical trials, pharmacovigilance and drug regulation in Latin America.Allele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers.Pharmacogenomics in pain treatment.Pharmacogenetic research activity in Central America and the Caribbean: a systematic review.Simultaneous Determination of Cytochrome P450 Oxidation Capacity in Humans: A Review on the Phenotyping Cocktail Approach.Ethnic background and CYP2D6 genetic polymorphisms in Costa Ricans.To Genotype or Phenotype for Personalized Medicine? CYP450 Drug Metabolizing Enzyme Genotype-Phenotype Concordance and Discordance in the Ecuadorian Population.
P50
Q27003942-D70216B1-E91D-4AB9-BE59-1E6B89DF1B62Q28071652-631E4AB9-0C1D-4C2A-8FE1-442FCEE00395Q28071652-88BD9179-F52B-495D-B178-0F622D1BB1E9Q30062193-6600D8B9-C2B3-4406-B760-58590F1DF5D7Q33588811-501217BA-A5FD-49A3-A6DB-C601EB228215Q33928098-EFBF5757-85CF-48C8-A039-6C233FC052D8Q34345969-C4D88778-04B6-4AEC-A8F8-0733CB8F366FQ34346356-0AD0786C-15CE-49D4-B132-2558689EDE12Q34347657-A6CF23AD-5A3A-480C-AE54-2311EF46B588Q34909452-4E2B09D4-FFE6-480A-902C-7EE25FD0C8A0Q34909452-CD09ED8E-DFF0-4905-BE95-EE25F9D7073CQ35800006-4562C8AA-3C4B-4A87-8AA7-7C2C3BA19F57Q35800006-E6CBD460-D92A-4364-A2B5-E342CDF717E2Q35883249-7876FEBE-8AED-4C46-A06A-231F2B628F1CQ35883249-B4711A89-B102-498D-89D0-2742A1FB4EC6Q36683874-73B7B1BE-E406-40BC-BF2E-AD39BCC57788Q36683874-E0FCB889-8DD2-4EEF-951B-512BC4B406BBQ36725206-0625DA0E-A7A5-41F2-BE2D-65C69E235C23Q36725206-2647A375-F860-4E1B-8BC6-F055498AB6F8Q36747019-E14B7B72-B155-41B7-BC06-C5B730FA1069Q36852406-07085A1D-B625-466A-8710-E3DA85A21A54Q36852406-90C848A8-20EE-4685-9322-933D752275BFQ37678050-54A6525F-77E7-4C7D-8326-0C05501407D3Q37678050-E55FF4DD-F458-4B66-8BA9-9EDFC6D33E57Q37697796-F7D0FBD1-5EC9-4663-AF0A-EA95C4BF3364Q37873934-84322F8B-51D0-48D6-AEDF-A845211293ABQ37873934-E9723B10-5DAC-4F63-A52E-37F39BF24CF5Q38061501-0DD1ABF3-1500-4BB4-A768-06FB5477340AQ38061501-AE37E6EF-C8F8-4C4B-BE52-4CEC3EE7B30FQ38074712-50DB08C9-E44A-42D2-B965-74C3B2F87D53Q38074712-D83592C6-814F-4568-96B0-5F1CBE445275Q38152907-A4607358-AF1A-4CE6-B95D-98BA6B4E1022Q38152907-ACFBD305-B443-4415-A996-5A5C38C2434DQ38154408-018CF745-5C4D-4BBA-87DC-3A49978764A3Q38154408-A1532CB3-AF3D-4B95-8C77-F270F4BCC100Q38177072-3A28F8DF-ECB7-4B81-BE1A-E311AA9C2AFAQ38177072-48392C9C-1C8B-441E-8574-88AE6A11AA4AQ38194380-8045DF3D-2B93-4B9B-B7F8-5748E3451D18Q38194380-C630DFBA-5B53-4D1E-809C-A9366C1CD984Q38223167-94CE3FE1-B23E-4C9C-9E9F-B11A1699DBFE
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Adrián Llerena
@ast
Adrián Llerena
@en
Adrián Llerena
@es
Adrián Llerena
@nl
type
label
Adrián Llerena
@ast
Adrián Llerena
@en
Adrián Llerena
@es
Adrián Llerena
@nl
altLabel
A Llerena
@ast
A Llerena
@en
A Llerena
@nl
Addrián Llerena
@en
LLERENA A
@en
prefLabel
Adrián Llerena
@ast
Adrián Llerena
@en
Adrián Llerena
@es
Adrián Llerena
@nl
P1053
F-1542-2015
P106
P1153
7005457720
P21
P31
P496
0000-0002-2602-1569
0000-0002-5663-7081